三重激动剂 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
PFOA can form as a breakdown product from a variety of precursor molecules. In fact, the main products of the fluorotelomer industry, fluorotelomer-based polymers, have been shown to degrade to form PFOA and related compounds, with half-lives of decades, both biotically and by simple abiotic reaction with water. It has been argued that fluorotelomer-based polymers already produced might be major sources of PFOA globally for decades to come. Other precursors that degrade to PFOA include 8:2 fluorotelomer alcohol (F(CF2)8CH2CH2OH), polyfluoroalkyl phosphate surfactants (PAPS), and possibly N-EtFOSE alcohol (F(CF2)8SO2N(Et)CH2CH2OH). When PTFE (Teflon) is degraded by heat (pyrolysis) it can form PFOA as a minor product. The Organisation for Economic Co-operation and Development (OECD) has compiled a list of 615 chemicals that have the potential to break down into perfluorocarboxylic acids (PFCA) including PFOA. However, not all 615 have the potential to break down to form PFOA. A majority of waste water treatment plants (WWTPs) that have been tested output more PFOA than is input, and this increased output has been attributed to the biodegradation of fluorotelomer alcohols. A current PFOA precursor concern are fluorotelomer-based polymers; fluorotelomer alcohols attached to hydrocarbon backbones via ester linkages may detach and be free to biodegrade to PFOA.
==== Menstrual bleeding ==== Tranexamic acid is sometimes used to treat heavy menstrual bleeding. When taken by mouth it both safely and effectively treats regularly occurring heavy menstrual bleeding and improves quality of life. Another study demonstrated that the dose does not need to be adjusted in females who are between ages 12 and 16. In a 10-year study, tranexamic acid and other oral medicines (mefenamic acid) were found to be as effective as the levonorgestrel intrauterine coil; the same proportion of women had not had surgery for heavy bleeding and had similar improvements in their quality of life.
Another incident during the war highlighted the question of large-scale Iraqi combat deaths. This was the "bulldozer assault", where two brigades from the US 1st Infantry Division (Mechanized) were faced with a large and complex trench network, as part of the heavily fortified "Saddam Hussein Line". After some deliberation, they opted to use anti-mine plows mounted on tanks and combat earthmovers to simply plow over and bury alive the defending Iraqi soldiers. Not a single American was killed during the attack. Reporters were banned from witnessing the attack, near the neutral zone that touches the border between Saudi Arabia and Iraq. Every American in the assault was inside an armored vehicle. Patrick Day Sloyan of Newsday reported, "Bradley Fighting Vehicles and Vulcan armored carriers straddled the trench lines and fired into the Iraqi soldiers as the tanks covered them with mounds of sand. 'I came through right after the lead company,' [Col. Anthony] Moreno said. 'What you saw was a bunch of buried trenches with peoples' arms and things sticking out of them.'" After the war, the Iraqi government said that only 44 bodies were found. In his book The Wars Against Saddam, John Simpson alleges that US forces attempted to cover up the incident.
=== Neurodegeneration and chronic pain === Big dynorphin is upregulated in spinal cord injury and chronic pain states, where excessive big dynorphin production through both opioid and non-opioid receptor mechanisms contribute to neuronal death, neuroinflammation, and pain chronification.
Sources: en.wikipedia.org
In January 1996, Wenger guided the club to their first piece of silverware as Nagoya defeated Sanfrecce Hiroshima to win the Emperor's Cup. Two months later they triumphed in the Super Cup, beating Yokohama Marinos 2–0. The success bolstered Nagoya's status in Japanese football, as well as Wenger's reputation; he was somewhat startled by the praise and idolisation that came his way. Midway through the 1996 league season, Wenger's former club Strasbourg enquired about the possibility of him returning to manage them. He turned down the offer, as he had been approached by Arsenal. David Dein had remained in contact with Wenger after their first meeting, and frequently sent him video tapes of matches to garner his opinions; "He was my personal pundit," the vice-chairman recalled. The Arsenal board rebuffed Dein's suggestion to appoint Wenger as early as 1995, but concerns over George Graham's successor Bruce Rioch meant they were more open-minded about hiring him since his stint in Japan. Wenger managed Nagoya for the final time on 28 August 1996 and delivered a farewell speech, thanking the fans in Japanese. Assessing his time in Japan, biographer Jasper Rees felt Wenger had left a mixed legacy at the club, as the immediate success was followed by fluctuating league finishes; it was not until 2010 that Nagoya (under Stojković) won their first title.
Undersecretary of State for Political Affairs from 2005 to 2008, has spoken about the visa denial by saying: "Bush administration officials, including me, believed this to be the right decision at the time." and has opined that "Now that it looks like Modi will become prime minister, it's reasonable for the Obama administration to say it's been 12 years [since the 2002 riots], and we'll be happy to deal with him"
About 98.5% of the oxygen in a sample of arterial blood in a healthy human breathing air at sea-level pressure is chemically combined with the hemoglobin. About 1.5% is physically dissolved in the other blood liquids and not connected to hemoglobin. The hemoglobin molecule is the primary transporter of oxygen in mammals and many other species. Hemoglobin has an oxygen binding capacity between 1.36 and 1.40 ml O2 per gram hemoglobin, which increases the total blood oxygen capacity seventyfold, compared to if oxygen solely were carried by its solubility of 0.03 ml O2 per liter blood per mm Hg partial pressure of oxygen (about 100 mm Hg in arteries). With the exception of pulmonary and umbilical arteries and their corresponding veins, arteries carry oxygenated blood away from the heart and deliver it to the body via arterioles and capillaries, where the oxygen is consumed; afterwards, venules and veins carry deoxygenated blood back to the heart. Under normal conditions in adult humans at rest, hemoglobin in blood leaving the lungs is about 98–99% saturated with oxygen, achieving an oxygen delivery between 950 and 1150 ml/min to the body. In a healthy adult at rest, oxygen consumption is approximately 200–250 ml/min, and deoxygenated blood returning to the lungs is still roughly 75% (70 to 78%) saturated.
1999: Established first quantifiable measurement of atractyloside in whole blood with high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS); 2001: GC-MS method required derivitization to detect atractyloside fragments; 2004: LC-MS (EI) using Waters Thermabeam detector resulted in complete fragmentation of the molecule; gentler ionization technique (ESI) was successfully used to detect ATR after chromatographic separation; 2006: Further development of procedure with ESI, eluent composition, and other experimental conditions, though still lacking specificity for forensic science. The procedure by Carlier et al. uses high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry (HPLC-HRMS/MS). After the extraction of ATR and CATR from the blood or urine sample, separation was performed by reverse-phase HPLC. The MS detection used a quadrupole-orbitrap high-resolution detector after heated electrospray in negative ionization mode. These extraction techniques yielded 71.1% and 48.3% of ATR and CATR, respectively, in which these results met acceptable international criteria for forensic science: precision (≤15% or ≤20% at the LLOQ) and accuracy (between 80 and 115% or 80-120% at the LLOQ). For reference, additional sources have fully characterized atractyloside in NMR, MS, IR, etc.
In linguistics, particularly in syntax, an element is described as in situ when it is pronounced in the same position where it receives its semantic interpretation. This concept is especially relevant in the analysis of wh- questions across languages. For example, in Mandarin Chinese and Kurdish, wh-elements remain in situ, producing structures analogous to "John bought what?" where the interrogative word occupies the same syntactic position as the direct object would in a declarative sentence ("John bought bread"). By contrast, languages like English and French typically employ wh-movement, where the interrogative element is displaced from its base position to the beginning of the clause, as in "What did John buy?" Here, the wh-word what has moved from its original post-verbal position to the sentence-initial position, leaving behind a trace or gap in the object position. This typological distinction between in situ wh-elements and moved wh-elements represents one of the fundamental parameters of variation in natural language syntax and has been extensively studied within generative grammar frameworks.
Sources: en.wikipedia.org
Desalting and buffer exchange are methods to separate soluble macromolecules from smaller molecules (desalting) or replace the buffer system used for another one suitable for a downstream application (buffer exchange). These methods are based on gel filtration chromatography, also called molecular sieve chromatography, which is a form of size-exclusion chromatography. Desalting and buffer exchange are two of the most common gel filtration chromatography applications, and they can be performed using the same resin. Desalting and buffer exchange both entail recovering the components of a sample in whatever buffer is used to pre-equilibrate the small, porous polymer beads (resin). Desalting occurs when buffer salts and other small molecules are removed from a sample in exchange for water (with the resin being pre-equilibrated in water). Buffer exchange occurs when the buffer salts in a sample are exchanged for those in another buffer.
Lebanese historian Philip K. Hitti commented on the relationship between the Druze and Christians in Lebanon, noting: "Folty Comte, a French scholar, was astonished by the remarkable similarity between the Druze and the Maronites (Christians) in their way of life, system of governance, dialect, customs, and public morals. Druze and Maronite families coexist harmoniously, and sometimes Maronites accompany their Druze neighbors to church". According to Hitti, the Druze believe in the efficacy of holy water blessed by a priest, and occasionally, if a missionary persists in evangelizing the Druze, they may accept the sacrament of baptism. Maretti, an Italian monk who visited the region in 1760, just before Folty's arrival, observed that the Druze show genuine affection and respect for Christians and their religion. He also noted that Druze pray in Greek Orthodox churches as they do in Turkish mosques. Historian Ray Jabre Mouawad observes that during the Ottoman period, there existed religious symbiosis between the Druze and Christians in Mount Lebanon. This period saw numerous cultural interactions, leading to shared symbols, the veneration of common saints, and the adoption of common terminology to refer to God. Evidence of these interactions can be found in the palaces and mausoleums of Druze leaders, as well as in Maronite and Greek Orthodox churches. According to scholar Pierre-Yves Beaurepaire, due to the Christian influence on the Druze faith, two Christian saints become the Druze's favorite venerated figures: Saint George and the Prophet Elijah.
Another report also published by the European Union Drugs Agency that conducted an analysis of wastewater samples for the presence of drug use in cities across Europe, found that more than 75% of cities had higher concentrations of cocaine and MDMA in wastewater during weekends indicating that these drugs are more often used in nightlife and recreational settings. It also found that of the cities tested about half of them found that ketamine use spiked on weekends. The same analysis of wastewater also found that cannabis, amphetamine and methamphetamine appear consistently throughout the week suggesting that people may use these drugs daily or for a non-recreational use.
== Honours == Du Vigneaud joined Alpha Chi Sigma while at the University of Illinois in 1930. He was elected to the United States National Academy of Sciences and the American Philosophical Society in 1944, and the American Academy of Arts and Sciences in 1948. He received the 1955 Nobel Prize in Chemistry "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone," a reference to his work on the peptide hormone oxytocin.
https://doi.org/10.1016/j.cell.2024.10.042 Schat, K. A., Kaspers, B., & Kaiser, P. (2014). Structure of the Avian Lymphoid System. In I. Olah, N. Nagy & L. Vervelde (Eds.), Avian Immunology (2nd ed., pp. 11-44). Academic Press.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.